1707 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia

Page last updated: 12 July 2022

Application Detail

Description of Medical Service

The primary clinical purpose for monitoring minimal residual disease (MRD) is to determine the response to treatment and the risk of leukaemia relapse. Next Generation Sequencing (NGS) is a method which can be used to quantify and evaluate MRD. It involves the collection of genomic DNA from bone marrow aspirate or peripheral blood, which is then processed to identify the frequency and distribution of clonal sequences consistent with a malignant lymphoma and to quantify MRD over time in these patients.

Description of Medical Condition

Acute lymphoblastic leukaemia (ALL) can occur at any age, but most cases arise in children younger than six years of age. Typical symptoms include fever, fatigue, bone or joint pain, bleeding, anorexia, abdominal pain, and hepatosplenomegaly. Despite most patients achieving a morphological remission, many will still have persistent MRD, which is the strongest predictor of relapse in ALL.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 2817 KB)
Application Form (Word 1229 KB)

Consultation Survey

Consultation Survey (PDF 691 KB)
Consultation Survey (Word 72 KB)

PASC Consultation
PASC consultation closed

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

PICO Confirmation (PDF 794 KB)
PICO Confirmation (Word 333 KB)

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

13-14 April 2022

ESC

6-7 October 2022

MSAC

24-25 November 2022